Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Shire's VPRIV Shows Improvement In Gaucher-Related Bone Disease - Quick Facts

Shire plc (SHP.L,SHPGY: Quote) reported new data that demonstrate velaglucerase alfa for injection or VPRIV, the company's enzyme replacement therapy for type 1 Gaucher disease, significantly improved selected markers of Gaucher-related bone disease in patients. The data presented show that VPRIV improves Gaucher-related bone disease by a sustained increase in bone mineral density or BMD.

Results from a head-to-head Phase III study of VPRIV and Cerezyme, and follow-on extension trial of VPRIV, show a statistically significant improvement in lumbar spine BMD in Gaucher patients starting at nine months of treatment with VPRIV. Clinically and statistically significant improvement from baseline in mean LS Z-score was witnessed at 9 months of treatment with VPRIV, but not in the cohort of patients treated with Cerezyme.

In Gaucher disease patients, BMD is generally reduced compared to individuals without Gaucher disease, often resulting in lower Z-scores.

Click here to receive FREE breaking news email alerts for Shire plc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Kraton Performance Polymers, Inc. (KRA), Wednesday reported second-quarter net income of $11.1 million or $0.33 per share, up from $3.8 million or $0.12 per share last year. Adjusted earnings improved to $0.46 per share from $0.15 per share last year. Revenues for the quarter dropped to $323.8... Organic grocer Whole Foods Market, Inc. said Wednesday after the markets closed that its third quarter profit rose 6.3% from last year, as same-store sales increased 3.9%. The company's quarterly earnings per share also came in above analysts' expectations, but its quarterly sales fell shy of analyst' forecast. Micro-blogging site Twitter Inc said Tuesday after the markets closed that its second quarter loss widened from last year, hurt mainly by stock-based compensation expense, even as revenue more than doubled thanks to growth in advertising. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.